1. Home
  2. MAIA vs VELO Comparison

MAIA vs VELO Comparison

Compare MAIA & VELO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • VELO
  • Stock Information
  • Founded
  • MAIA 2018
  • VELO 2014
  • Country
  • MAIA United States
  • VELO United States
  • Employees
  • MAIA N/A
  • VELO N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • VELO Industrial Machinery/Components
  • Sector
  • MAIA Health Care
  • VELO Technology
  • Exchange
  • MAIA Nasdaq
  • VELO Nasdaq
  • Market Cap
  • MAIA 56.7M
  • VELO 63.7M
  • IPO Year
  • MAIA 2022
  • VELO N/A
  • Fundamental
  • Price
  • MAIA $1.32
  • VELO $5.88
  • Analyst Decision
  • MAIA
  • VELO Strong Buy
  • Analyst Count
  • MAIA 0
  • VELO 1
  • Target Price
  • MAIA N/A
  • VELO $6.00
  • AVG Volume (30 Days)
  • MAIA 594.6K
  • VELO 938.8K
  • Earning Date
  • MAIA 11-11-2025
  • VELO 11-26-2025
  • Dividend Yield
  • MAIA N/A
  • VELO N/A
  • EPS Growth
  • MAIA N/A
  • VELO N/A
  • EPS
  • MAIA N/A
  • VELO N/A
  • Revenue
  • MAIA N/A
  • VELO $43,765,000.00
  • Revenue This Year
  • MAIA N/A
  • VELO $330.48
  • Revenue Next Year
  • MAIA N/A
  • VELO N/A
  • P/E Ratio
  • MAIA N/A
  • VELO N/A
  • Revenue Growth
  • MAIA N/A
  • VELO N/A
  • 52 Week Low
  • MAIA $1.27
  • VELO $1.43
  • 52 Week High
  • MAIA $3.48
  • VELO $29.25
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 34.23
  • VELO N/A
  • Support Level
  • MAIA $1.65
  • VELO N/A
  • Resistance Level
  • MAIA $1.97
  • VELO N/A
  • Average True Range (ATR)
  • MAIA 0.12
  • VELO 0.00
  • MACD
  • MAIA -0.05
  • VELO 0.00
  • Stochastic Oscillator
  • MAIA 4.45
  • VELO 0.00

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About VELO Velo3D Inc. Common stock

Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.

Share on Social Networks: